Inventiva S.A. (IVEVF)

Market Cap	1.16B +403.0%
Revenue (ttm)	19.93M -10.4%
Net Income	-365.31M
EPS	-4.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	600
Average Volume	1,193
Open	4.160
Previous Close	4.120
Day's Range	4.140 - 4.500
52-Week Range	2.280 - 4.590
Beta	0.89
RSI	53.54
Earnings Date	Mar 30, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-β, a pre-clinical program for th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 84
• Stock Exchange: OTCMKTS
• Ticker Symbol: IVEVF

Financial Performance

In 2024, Inventiva's revenue was 14.09 million, a decrease of -38.24% compared to the previous year's 22.82 million. Losses were -184.21 million, 66.8% more than in 2023.

Financial numbers in EUR